

Views and Perspectives

CME

Psychological Risk Factors in Headache

Robert A. Nicholson, PhD; Timothy T. Houle, PhD; Jamie L. Rhudy, PhD; Peter J. Norton, PhD

Headache is a chronic disease that occurs with varying frequency and results in varying levels of disability. To date, the majority of research and clinical focus has been on the role of biological factors in headache and headache-related disability. However, reliance on a purely biomedical model of headache does not account for all aspects of headache and associated disability. Using a biopsychosocial framework, the current manuscript expands the view of what factors influence headache by considering the role psychological (i.e., cognitive and affective) factors have in the development, course, and consequences of headache. The manuscript initially reviews evidence showing that neural circuits responsible for cognitive-affective phenomena are highly interconnected with the circuitry responsible for headache pain. The manuscript then reviews the influence cognitions (locus of control and self-efficacy) and negative affect (depression, anxiety, and anger) have on the development of headache attacks, perception of headache pain, adherence to prescribed treatment, headache treatment outcome, and headache-related disability. The manuscript concludes with a discussion of the clinical implications of considering psychological factors when treating headache.

Key words: headache, self-efficacy, locus of control, biopsychosocial, psychological, negative affect

(*Headache* 2007;47:413-426)

Headache is currently conceptualized as a chronic disorder with acute episodes of pain occurring intermittently lasting anywhere from minutes to days. For a significant number of patients, these attacks occur once a month or more and result in varied levels of disability.¹⁻⁴ Clinicians thus need to consider what factors influence the development, course, and severity of individual headache attacks and subsequent disability in order to minimize the frequency of attacks, reduce

their severity, and limit their impact on functioning. To date, the overwhelming majority of research and clinical interest has focused on biological influences. These efforts have resulted in significant steps forward in the treatment and prevention of headache and its related disability; however, this research has also revealed that biological factors alone fail to account for all aspects of headache and disability. Psychological factors such as headache management locus of control and self-efficacy, and negative affect/emotional states can alter the likelihood of a headache attack being triggered, the perceived severity of headache pain, the impact headache has on functioning, and treatment prognosis.^{5,6} Unfortunately, psychological factors are typically considered relevant only in cases where the patient presents with significant psychopathology.⁷⁻⁹ The purpose of the current manuscript is to describe the rationale for envisioning headache within a biopsychosocial framework, review evidence supporting this view, and consider clinical implications of considering psychological factors when treating headache.

For CME, visit <http://www.headachejournal.org>

From the Department of Family Medicine, St. Louis University School of Medicine, and Ryan Headache Center, St. Louis, MO (Dr. Nicholson); Department of Anesthesiology, Wake Forest University Medical School, Winston Salem, NC (Dr. Houle); Department of Psychology, University of Tulsa, Tulsa, OK (Dr. Rhudy); and Department of Psychology, University of Houston, Houston, TX (Dr. Norton).

Address all correspondence to Dr. Robert Nicholson, St. Louis University School of Medicine, Department of Family Medicine, 1402 S. Grand Blvd. Donco Bldg., 2nd Floor, St. Louis, MO 63104.

Accepted for publication October 2, 2006.

A BIOPSYCHOSOCIAL MODEL OF HEADACHE

The biopsychosocial model can be summarized as considering the multidirectional relationships between biological (physiological), psychological (behavioral), and social (environmental) factors in the explanation of disease.^{10,11} Whereas a biomedical model of disease focuses exclusively on biological processes and relinquishes psychological processes to the theatre of the mind, the biopsychosocial model attempts to overcome Cartesian dualism by recognizing that biological, psychological, and social/environmental influences are scientifically inseparable.

To date, the overwhelming majority of empirical and theoretical efforts to elucidate the development, course, and consequences of individual headache attacks have used a biomedical model. However, the clinical scientist and practicing clinician who regularly treat headache recognize that the experiences of many headache patients do not match the expectations emanating from a biomedical model. As a result, there is growing attention to the interplay of biological, psychological (made up primarily of cognitive and affective processes), and social processes in headache.¹⁴⁻¹⁶ Viewing headache as a biopsychosocially influenced disease does not discount the importance of biological factors; instead, it provides a more complete account of what influences the development, course, and consequences of headache in the clinical setting. Given the emphasis on interdependent influences of biological, psychological, and social factors, it may seem surprising that the current manuscript focuses almost exclusively on psychological factors. This is not intended to suggest that psychological factors are more important than biological or social factors (since the biopsychosocial model holds that each factor's influence is fluid), but is rather a function of the paucity of literature to date reviewing the influence of psychological factors on headache.

CENTRAL-LEVEL PSYCHOLOGICAL INFLUENCES ON PAIN

Prior to focusing on specific psychological (cognitive and affective) factors that influence headache, the manuscript briefly reviews evidence showing that neural circuits responsible for cognitive-affective phe-

nomena are highly interconnected with the circuitry responsible for headache pain.

By definition, pain is a psychological construct referring to the perception of unpleasant or aversive sensations.^{17,18} Multiple brain regions process different aspects of a pain message, making pain an event stemming from a complex neuromatrix.¹⁹⁻²² Many of the regions associated with pain processing are also involved with other psychological phenomena (eg, emotions, attention, stress),²³⁻³⁰ therefore, modulation of pain by psychological factors may occur through these shared circuits, altering the pain signal within brain.

The best known CNS mechanism that modifies pain is a circuit that comprises the periaqueductal gray (PAG), 5-Hydroxytryptamine (5-HT) neurons of the rostral ventromedial medulla (RVM), and norepinephrine (NE) neurons of the dorsolateral pontomesencephalic tegmentum (DLPT).³¹ At least some of the pain relieving effects of opioid analgesics, 5-HT agonists, and NE agonists occur via this circuit.³¹ The PAG appears particularly influential in migraine.³² For example, the placement of electrodes into the PAG can induce migraine-like pain³³ and neuroimaging studies show that activity within the PAG and other brainstem structures is associated with migraine pain.³⁴

This PAG-RVM-DLPT circuit receives input from multiple forebrain regions involved with psychological processes—particularly the limbic system. For example, the amygdala, an area known to be important for emotion,²⁹ can activate this circuit and appears critical for modulation of pain by cognitive-emotional factors.³⁵⁻⁴⁰ Additionally, the anterior cingulate cortex, orbitofrontal cortex, insula, and hippocampus are implicated in pain modulation resulting from attention, placebo, expectation, perceptions of controllability, and/or anxiety.⁴¹⁻⁴⁸ These findings support the utility of a biopsychosocial view of headache.^{49,50} Indeed, the interconnectivity between psychological and biological systems can explain how transient, experimentally-induced states can lead to headache,^{51,52} and how long term changes (through neuroplasticity/sensitization) in these systems may influence headache chronification and lead to comorbid headache and mood/cognitive disorders.^{53,54}

In summary, psychological factors can influence headache pain via various CNS pathways. However, it is important to identify specific factors that are influential. The next sections review specific cognitive and affective factors that influence the development, course, and consequences of headache.

HEADACHE BELIEFS AND COGNITIONS

Cognitive processes encompass the thoughts, beliefs, attributions, and attitudes people utilize when negotiating their environment. As it relates to headache, cognitions influence whether a patient engages in behaviors that lessen the likelihood of having a headache attack, adheres to medication regimen, and how the patient copes with the headache attack (thus influencing headache-related disability). Although numerous cognitive processes can influence headache and disability, 2 types of cognitions are particularly influential: locus of control (LOC) beliefs and self-efficacy (SE) beliefs.

Locus of Control (LOC).—LOC beliefs concern the degree to which an individual perceives that an event is under his/her personal control. These beliefs range from a completely internal LOC (where the individual perceives the event as totally under his/her control), to a completely external LOC (where the event is perceived as totally outside the individual's realm of influence). Individuals typically experience LOC about an event that falls somewhere between these 2 extremes. In most situations, having less internal LOC (ie, more external LOC) negatively influences affective (eg, increased dysphoric feelings), behavioral (eg, less likely to use active coping),⁵⁵⁻⁵⁷ and physiological (eg, NE depletion and increased 5-HT sensitization)^{58,59} responses to an event.⁵⁶⁻⁵⁸ If perceived internal LOC remains low for an extended period then the individual may perceive that the situation is “hopeless” and thus “gives up,” resulting in more pronounced affective, behavioral, and physiologic problems.

As it pertains to headache, 3 loci have been identified that determine who the individual views as controlling the onset, course, and consequences of headache.^{9,60} These 3, internal LOC (“I am the key factor in controlling my headaches”), external-chance LOC (“nothing predicts my headaches”), and external-health care professionals LOC (“only my

doctor and prescription medication can control my headaches”) are present to varying degrees for all individuals. There may also be variability in an individual's LOC as it relates to different phases of a headache attack and its consequences. Research has shown that a high internal LOC is associated with better headache treatment outcome⁶¹ and less headache-related disability.⁶² Conversely, patients with low internal LOC are less likely to engage in behaviors that reduce the likelihood of a headache attack (eg, managing headache triggers), reduce/eliminate headache pain (eg, not seeing themselves as responsible for taking medication as prescribed), and minimize headache-related disability. As it pertains to external LOC, patients who believe their headaches are controlled primarily by chance factors report higher levels of depression, are less likely to engage in adaptive coping strategies, and experience more headache-related disability.⁶³ Patients who believe that health care professionals are the primary influence on headaches report higher levels of medication use,⁶³ which may put these individuals at greater risk for medication overuse headache. Thus, a higher internal LOC and lower external LOC is typically desirable for optimal outcome.

Self-Efficacy (SE).—SE refers to an individual's belief that he/she can successfully engage in a course of action to produce a desired outcome.^{64,65} SE beliefs exist for any potential behavior in which the individual may engage and are situation specific. SE beliefs vary across people and situations and can be modified over time as a result of successful or unsuccessful experiences.⁶⁴ For example, individuals possess SE beliefs about their cognitive, behavioral, and affective responses to a stressor.⁶⁶

The influence of SE on headache has received considerable attention. The majority of this attention has focused on the role of SE in predicting headache treatment response, particularly as a potential mediator or moderator of treatment outcome.⁶⁷⁻⁷¹ Seminal work concerning what mediates patient improvement during biofeedback training indicated that changes in SE were the mechanism of change.⁷²⁻⁷⁵ Baseline self-efficacy predicts differential response to combined pharmacologic and behavioral treatment⁷⁶ and changes in SE correlate with changes in headache frequency.^{77,78}

SE also influences how one manages headache and disability. Individuals possess SE beliefs for managing modifiable triggers, adhering to treatment regimens, and coping with pain.⁷⁹ High levels of SE are associated with less dysphoric and anxious feelings⁸⁰ and moderate the influence of perceived stress on headache frequency.⁸¹ Low SE for coping with a stressor increases autonomic arousal⁸² thus making one more susceptible to experiencing a headache.^{12,83-85} SE has also been proposed as a predictor of headache-related disability and preliminary findings appear to support this hypothesis.⁸⁶

LOC and SE are related, yet independent concepts. Together they represent the manner whereby an individual determines whether or not to engage in behaviors that lessen the likelihood of a headache attack, whether to adhere to pharmacologic treatment recommendations, and/or whether to cope with headache in a manner that reduces headache-related disability. Thus, patients' LOC and SE beliefs are relevant issues to consider in treatment formulation.⁸⁷

NEGATIVE AFFECT AND EMOTIONAL STATES

Pain involves both a sensory and an affective component.¹⁸ Pain-related affect is almost always aversive and involves "negative affect" (NA). NA is a construct consisting of a "triumvirate" of negative emotions: anxiety, depression, and anger.^{88,89} NA emotions influence the course and impact of headache within the normal range of affective experience, not simply when an Axis I disorder is present. These emotions can influence the likelihood an individual will experience a headache attack,⁹⁰⁻⁹⁵ the intensity of headache pain,⁹⁶⁻⁹⁸ and headache-related disability.^{6,9,99-104} NA comprises a basic unpleasant-defensive motivation system involving a complex neural circuit that can provoke varying degrees of neural and physiological activation that can potentially onset or exacerbate a headache.¹⁰⁵ At a central level, it has recently been hypothesized that anxious/stressful feelings may trigger activation in the PAG and paraventricular hypothalamic nucleus.¹⁰⁶ This activates a series of events in the superior salivatory nucleus (SSN) and trigeminovascular system that results in migraine pain.¹⁰⁶

As noted earlier, the amygdala and septo-limbic system play a role in the experience of emotion and the cognitive-emotional modulation of pain. At a peripheral level, NA can instigate adrenal release, change blood lipid levels, infuse sugar into the blood stream, increase heart rate, respiration, and muscle tension. Any one or combination of these processes could trigger a headache attack.¹⁰⁷

Potential neurochemical links between NA and headache include 5-HT and γ -aminobutyric acid (GABA) dysregulation, which both have been implicated in NA emotions and headache. Dysregulated GABA is implicated in anxiety¹⁰⁸⁻¹¹⁰ and medications that enhance GABA-ergic function are useful in preventing migraine headache, perhaps by reducing cortical excitability.^{12,111,112} Dysregulated 5-HT may be responsible for headache, anxiety, and depressed mood.^{113,114} The mechanisms whereby anger and anger expression influence headache activity are unknown; however, its influence likely comes from limbic system activation.¹¹⁵⁻¹¹⁷ Although anxiety, depression, and anger together create NA, each appear to uniquely influence headache and thus warrant independent review.

Anxiety.—Anxiety is an aversive state of worry, fear, uneasiness, or apprehension "resulting from feelings of being unable to predict, control or obtain desired outcomes"^{118,119} in regards to a specific situation (eg, an upcoming evaluation at work, having enough money to make credit card and utility payments for the month) but can also be more nebulous (eg, career, family, finances). Patients often use the term "anxiety" and "stress" interchangeably, as the concepts are highly correlated.¹²⁰ It is likely that an individual who responds anxiously when exposed to a stressor will become stressed about that response, which then heightens anxiety, and thus creates a vicious anxiety/stress cycle.

Although much attention has been focused on the relationship between depressive symptoms and headache, anxious feelings may be even more prevalent among headache sufferers.^{85,121-125} Anxious/stressful feelings are one of the most common headache triggers and individuals with headache are more anxious than persons without pain.^{91,126-128}

Heightened anxiety can increase headache pain intensity^{129,130} and reduced anxiety is associated with decreased headache frequency over time.⁹¹

Perhaps the greatest influence anxious feelings have is on headache-related disability. Increased anxiety among headache sufferers is associated with greater disability, poorer quality of life, and increased cost of care.^{93,122,127,131-134} Interestingly, one recent study found less anxious/worried feelings after 6 months was a stronger predictor of lower headache impact than changes in headache frequency or changes in medication.⁷⁶

Another way whereby anxiety can precipitate the likelihood of having a headache attack, exacerbate pain intensity, and make headaches more disabling is through a concept termed "Anxiety Sensitivity" (AS).^{107,135-138} AS is a dispositional construct wherein individuals higher on AS react fearfully to unusual bodily sensations or physiological symptoms of anxiety or fear. For example, a pounding heart might be interpreted by someone high on AS as evidence of cardiac problems or an impending heart attack. This catastrophic interpretation may then lead to sympathetic activation and (via a negative feedback loop) further increased heart rate. The intensification of the symptoms (eg, heart rate) strengthens the belief in the negative interpretation (eg, cardiac problems), leading to greater autonomic activation and further catastrophic beliefs, culminating through a vicious cycle into a panic attack. Similar observations of symptom misinterpretation have been described in hypochondriasis¹³⁹ and chronic musculoskeletal pain.¹⁴⁰

Although the study of AS in headache is in its infancy, 3 possible relationships exist. First, and most likely, is that AS increases headache-related disability. Individuals high in AS may misinterpret innocuous sensations as evidence of possible headache onset, thus making them more likely to exit and subsequently avoid situations or activities around which those symptoms occurred.¹³⁶ Second, AS may amplify headache pain in much the same way that high AS amplifies a panic attack. If early headache symptoms are interpreted negatively and provoke anxiety and fear, sympathetic nervous system activation could lead to physiological increases in heart and respiration rates, blood sugar and lipid levels, and general muscle ten-

sion that might, in turn, intensify headache pain. Third, it is plausible that high AS could trigger a headache attack through a similar mechanism; that is, the misinterpretation of innocuous sensations may cause anxiety and sympathetic arousal which, in turn, may provoke a headache attack. One interesting study reported that heightened AS may reduce the likelihood that rescue medications will be taken as directed.¹⁴¹ However, before any conclusions can be made about the relationship between AS and headache, more empirical investigation is needed to establish the parameters of this relationship.

Depression.—Depression as a clinical syndrome is commonly described by feelings of sadness, despair, emptiness, or loss of interest or pleasure in activities occurring nearly every day for more than a 2-week period.¹⁴² Although depression is a clinical disorder, all individuals experience transitory dysphoric feelings of sadness, despair, emptiness, or loss of interest or pleasure in activities in the course of their lives.

Dysphoric feelings are higher among those with headache than those without.^{100,101,143-145} Heightened dysphoria increases the likelihood that stress will trigger a headache, increases headache pain severity, is a negative prognosticator for response to treatment,^{16,93,94,146,147} and negatively influences a patient's level of satisfaction with his/her care.¹²² In addition, hopelessness (a cognitive perception characterized by low internal LOC, low SE, and heightened pessimism) often accompanies dysphoric feelings¹⁴⁸ and increased headache-related disability.^{93,101,103,143,149-151}

Anger.—Anger is a state of displeasure ranging in intensity from mild irritation to intense fury in response to a perceived wrong that threatens the well-being of an individual or others with whom the individual identifies.¹⁵²⁻¹⁵⁴ There is a great deal of inter- and intra-individual variability in the level of emotional intensity and physiological arousal one experiences when angry.¹⁵²⁻¹⁵⁶ Although the extent whereby one becomes angry can influence the course and outcome of diseases,¹⁵⁷⁻¹⁵⁹ how the individual expresses/manages their anger has a far greater impact on disease course and impact.^{159,160} When considering how anger is expressed, researchers have identified 2 distinct styles of anger expression: anger-in and anger-out. Anger-in is when an individual does not outwardly

express their anger, but experiences increased internal arousal^{161,162} whereas anger-out involves physical acts (eg, slamming doors) or verbal expression (eg, sarcastic remarks^{162,163}). Being able to express anger appears to lessen the negative impact of anger on emotional and physical function.¹⁶³⁻¹⁶⁵ However, expressing anger can have negative consequences such as being “socially unacceptable,” creating unpleasantness (“if you can’t say anything nice, don’t say anything at all”), and instigating perceived negative consequences.^{152,155,166}

Individuals with headache are more likely to hold their anger in than persons without headaches.^{100,104,144,145,167} Individuals who hold anger in experience increased pain severity⁹⁸ and failure to express anger leads to more disability.^{96,98,101,124,168,169} However, being extremely high on anger-out increases pain sensitivity and disability.^{170,171} Overall, either too much expression or inhibition of anger appears to have deleterious effects. Failure to adequately express one’s anger also negatively influences patient-provider communication.¹²³ This lessens the likelihood that headaches will be diagnosed adequately¹²³ and is a poor prognosticator of treatment outcome.¹⁶⁰

Overall, inadequately managed NA increases the individual’s risk for experiencing more headache attacks, more intense headache pain, and more headache-related disability via central, neurochemical, and peripheral routes.

CLINICAL IMPLICATIONS

The current paper has argued that viewing headache as a biopsychosocially influenced disease is more appropriate than considering biological factors alone. The paper has focused on how specific psychological factors (LOC, SE beliefs, and NA) can influence the development, course, and consequences of headache. Taking a biopsychosocial view of headache presents both a challenge and an opportunity to the practicing physician. The challenge is that these factors interact to influence the development, course, and consequences of headache in ways heretofore not fully elucidated. On the other hand, taking such a view allows the physician to utilize their clinical acumen by considering all aspects of the individual (biological, psychological, and social) when establishing treatment

recommendations. Listed below are examples of how psychological factors can influence treatment recommendations and treatment outcome along with suggestions for how to address psychological factors.

1. Recognizing and managing triggers is recommended to prevent headache attacks and to prevent episodic headaches from becoming chronic.^{172,173} However, if a patient believes they have little or no influence on whether they experience a headache attack (low internal LOC) and low SE for managing headache triggers, then it is unlikely they will follow this recommendation. Educating the patient about how triggers influence a headache attack, and how managing triggers can reduce the number of headache attacks, increases internal LOC. Having patients keep regular diaries of potential headache triggers allows the patient to see how triggers are related to headache.¹⁷⁴ Similarly, teaching skills for self-managing triggers will increase SE. Also, an individual with catastrophic fear about being exposed to a potential trigger will need to become aware that triggers can set the stage for headache, but exposure to a trigger does not mean they will experience a debilitating headache. The sage physician will elicit examples from the patient (or talk about other similar patients’ experiences) in which exposure to the triggers did not result in a severe, debilitating headache, or in which the individual took medication (eg, triptan) that lessened/aborted the headache.
2. Taking headache medication as prescribed is imperative for maximum efficacy. However, a patient with low SE for taking medication will be less adherent to protocol. Having a medical staff member (eg, nurse) teach the individual (or model for them) how/when/why to take medication (eg, taking a triptan at the appropriate time) and then following up with the patient to reinforce adherence or discuss barriers to adherence will raise SE and increase adherence.
3. Current conceptualizations of headache, especially migraine, suggest that a “hyper excitable” brain is an important factor for experiencing

headache.^{84,175,176} Thus, interventions that seek to reduce the brain's excitability are theoretically sound. Patients whose stress, anxiety, and/or anger are not well managed will have heightened arousal and thus be at greater risk for experiencing a headache attack because of their influence on the brain's chemistry and excitability. The physician who normalizes the patient's need for managing stress ("A lot of patients find that doing something to take the edge off helps them deal better with life") and encourages the patient to use evidence-based relaxation and stress management strategies will make it more likely the patient will adopt such strategies.

As the examples above have noted, there are clinically sound strategies for addressing psychological factors in headache. Although no validated treatment algorithms exist for knowing how and when to address psychological factors, there are certain strategies that likely enhance the efficacy of ongoing pharmacologic intervention. An efficacious and easily administered strategy is relaxation/stress-management.¹⁷⁷⁻¹⁷⁹ Although most physicians appreciate the potential benefits of managing stress, many are surprised that these strategies can also improve SE for managing headache (and likely create a more internal LOC). Education strategies (eg, recognizing and managing triggers, taking medication as prescribed, understanding the "migraine" brain) can also improve patient outcomes and increase SE.^{76,78,180}

One of the difficulties of using these strategies has been integrating them into ongoing pharmacologic care and/or connecting the patient with a behavioral specialist. However, using a self-management model whereby the patient and physician partner together to maximize treatment benefits by allowing the patient a more active role in managing their disease has been used successfully in other chronic diseases and would likely work in headache as well.⁸⁷

Addressing psychological factors is a low priority for certain headache sufferers. This includes patients who experience headache once a month or less, whose acute medications are fully efficacious at treating their headaches, and who experience no more

than mild headache-related disability. There is also a subset of patients whose presentation make it highly unlikely that addressing psychological needs alone will have significant benefits until other issues are addressed.¹⁸¹ This includes patients with continuous or near-continuous headaches, high levels of medication overuse, and those with severe depression. However, relatively few headache sufferers presenting for treatment fall into these categories and thus, almost all headache patients presenting for treatment will benefit from considering psychological risk factors in headache and addressing them as appropriate.

Acknowledgments: The authors would like to thank Ms. Megan Roche for her assistance in preparing the manuscript, and Drs. Donald Penzien and Jeanetta Raino for their guidance in the direction of the manuscript. Supported by grant 1K23NS048288-01A2 from the National Institutes of Health.

Conflict of Interest: None

REFERENCES

1. Lipton RB, Stewart WF, von Korff M. Burden of migraine: Societal costs and therapeutic opportunities. *Neurology*. 1997;48:4-9.
2. Lipton RB, Liberman J, Kolodner K, Bigal ME, Dowson A, Stewart WF. Migraine headache disability and health-related quality-of-life: A population-based case-control study from England. *Cephalalgia*. 2003;23:441-450.
3. Stewart SH, Lipton RB, Simon DJ. Work-related disability: Results from the American Migraine Study. *Cephalalgia*. 1996;16:231-238.
4. Lipton R, Hamelsky SW, Stewart W. Epidemiology and impact of migraine. In: Silberstein S, Lipton R, Dalessio D, eds. *Wolff's Headache and Other Head Pain*. New York: Oxford University Press; 2001:85-107.
5. Baskin M, Ahluwalia HK, Resnicow K. Obesity intervention among African-American children and adolescents. *Pediatric Clin North Am*. 2001;48:1027-1039.
6. Lake A, Rains J, Penzien D, Lipchik G. Headache and psychiatric comorbidity: Historical context, clinical implications, and research relevance. *Headache*. 2005;45:493-506.
7. Lake A, Lipchik G, Penzien D, Rains J, Saper J, Lipton R. An introduction to psychiatric comorbidity

- with chronic headache: Evidence-based clinical implications. *Headache*. 2006;46.
8. Hamelsky S, Lipton R. Psychiatric comorbidity of migraine. *Headache*. 2006;46.
 9. Penzien DB, Rains JC, Holroyd KA. Psychological assessment of the recurrent headache sufferer. In: Tollison CD, Kunkel RS, eds. *Headache: Diagnosis and Treatment*. Baltimore: Will & Wilkins; 1993:39-49.
 10. Engel GL. The need for a new medical model: A challenge for biomedicine. *Science*. 1977;196:129-136.
 11. Camic P, Knight SE. *Clinical Handbook of Health Psychology: A Practical Guide to Effective Interventions*. Seattle, WA: Hogrefe & Huber; 1998.
 12. Welch K. Brain hyperexcitability: The basis for antiepileptic drugs in migraine prevention. *Headache*. 2005;45:S25-S32.
 13. Goadsby PJ. Migraine pathophysiology. *Headache*. 2005;45(Suppl 1):S14-S24.
 14. Andrasik F, Flor H, Turk DC. An expanded view of psychological aspects in head pain: The biopsychosocial model. *Neurol Sci*. 2005;26:S87-S91.
 15. Loder E, Biondi D. General principles of migraine management: The changing role of prevention. *Headache*. 2005;45:S33-S47.
 16. Lipton RB, Silberstein SD, Saper JR, Bigal ME, Goadsby PJ. Why headache treatment fails. *Neurology*. 2003;60:1064-1070.
 17. Merskey H, Bogduk N, eds. IASP Task Force on Taxonomy. *Classification of Chronic Pain: Description of Chronic Pain Syndromes and Definition of Pain Terms*. 2nd ed. Seattle: IASP Press; 1994.
 18. International Association for the Study of Pain. Classification of chronic pain. *Pain*. 1986(suppl 3):S1-S226.
 19. Price D. Psychological and neural mechanisms of the affective dimension of pain. *Science*. 2000;288.
 20. Rainville P, Carrier B, Hofbauer R, Bushnell MC, Duncan G. Dissociation of sensory and affective dimensions of pain using hypnotic modulation. *Pain*. 1999;82:159-171.
 21. Rainville P, Duncan G, Price D, Carrier B, Bushnell MC. Pain affect encoded in human anterior cingulate but not somatosensory cortex. *Science*. 1997;277:968-971.
 22. Melzack R. From the gate to the neuromatrix. *Pain*. 1999;(suppl 6):S121-S126.
 23. Phan K, Wager T, Taylor S, Liberzon I. Functional neuroanatomy of emotion: A meta-analysis of emotion activation studies in PET and fMRI. *Neuroimage*. 2002;16:331-348.
 24. Cardinal R, Parkinson J, Hall J, Everitt B. Emotion and motivation: The role of the amygdala, ventral striatum, and prefrontal cortex. *Neurosci Biobehav Rev*. 2002;26:321-352.
 25. Davis M, Hitchcock J, Bowers M, Berridge C, Melia K, Roth R. Stress-induced activation of prefrontal cortex dopamine turnover: Blockade by lesions of the amygdala. *Brain Res*. 1994;664:207-210.
 26. Gallagher M, Schoenbaum G. Functions of the amygdala and related forebrain areas in attention and cognition. *Ann N Y Acad Sci*. 1999;877.
 27. Han C, O'Tuathaigh C, vanTrigt L, et al. Trace but not delay fear conditioning requires attention and the anterior cingulate cortex. *Proc Natl Acad Sci*. 2003;100:13087-13092.
 28. Lane RD, Reiman E, Bradley M, et al. Neuroanatomical correlates of pleasant and unpleasant emotion. *Neuropsychologia*. 1997;35:1437-1444.
 29. LeDoux J. Emotion circuits in the brain. *Ann Rev Neurosci*. 2000;23:155-184.
 30. Sapolsky R. Stress and plasticity in the limbic system. *Neurochem Res*. 2003;28:1735-1742.
 31. Fields H. State-dependent opioid control of pain. *Nat Rev*. 2004:565-575.
 32. Welch K, Nagesh V, Aurora S, Gelman N. Periaqueductal gray matter dysfunction in migraine: Cause or the burden of illness? *Headache*. 2001;41:629-637.
 33. Raskin N, Hosobuchi Y, Lamb S. Headache may arise from perturbation of brain. *Headache*. 1987;27:416-420.
 34. Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. *Nat Med*. 1995:658-660.
 35. Manning B. A lateralized deficit in morphine antinociception after unilateral inactivation of the central amygdala. *J Neurosci*. 1998;18:9453-9470.
 36. Crown E, King T, Meagher MW, Grau J. Shock-induced hyperalgesia: III. Role of the bed nucleus of the stria terminalis and amygdaloid nuclei. *Behav Neurosci*. 2000;114:561-573.
 37. Fox R, Sorenson C. Bilateral lesions of the amygdala attenuate analgesia induced by diverse environmental challenges. *Brain Res*. 1994;648:215-221.
 38. Helmstetter F, Bellgowan P. Lesions of the amygdala block conditional hypoalgesia on the tail flick test. *Brain Res*. 1993;612:253-257.

39. Rhudy JL, Meagher MW. The role of emotion in pain modulation. *Curr Opin Psychiatr.* 2001;14:241-245.
40. Watkins L, Wiertelak E, Maier S. The amygdala is necessary for the expression of conditioned but not unconditioned analgesia. *Behav Neurosci.* 1993;107:402-405.
41. Bantick S, Wise R, Ploghaus A, Clare S, Smith S, Tracey I. Imaging how attention modulates pain in humans using functional MRI. *Brain.* 2002;125:310-319.
42. Dowman R. Distraction produces an increase in pain-evoked anterior cingulate activity. *Psychophysiology.* 2004;41:613-624.
43. Hsieh J, Stone-Elander S, Ingvar M. Anticipatory coping of pain expressed in the human anterior cingulate cortex: A positron emission tomography study. *Neurosci Lett.* 1999;262:61-64.
44. Petrovic P, Dietrich T, Fransson P, Andersson J, Carlsson K, Ingvar M. Placebo in emotional processing—induced expectations of anxiety relief activate a generalized modulatory network. *Neuron.* 2005;46:957-969.
45. Ploghaus A, Becerra L, Borras C, Borsook D. Neural circuitry underlying pain modulation: Expectation, hypnosis, placebo. *Trends Cogn Sci.* 2003;7:197-200.
46. Rainville P, Hofbauer R, Bushnell MC, Duncan G, Price D. Hypnosis modulates activity in brain structures involved in the regulation of consciousness. *J Cogn Neurosci.* 2002;14:887-901.
47. Salomons T, Johnstone T, Backonja M, Davidson R, et al. Perceived controllability modulates the neural response to pain. *J Neurosci.* 2004;24:7199-7203.
48. Ploghaus A, Tracey I, Gati J, et al. Dissociating pain from its anticipation in the human brain. *Science.* 1999;284:1979-1981.
49. Bakal D. *Psychobiology of Chronic Headache.* New York: Springer; 1982.
50. Bakal D, Kaganov J. Symptom characteristics of chronic and non-chronic headache sufferers. *Headache.* 1979;19:285-289.
51. Bayer T, Baer P, Early C. Situational and psychophysiological factors in psychologically induced pain. *Pain.* 1991;44:45-50.
52. Gannon L, Haynes S, Cuevas J, Chavez R. Psychophysiological correlates of induced headaches. *J Behav Med.* 1987;10:411-423.
53. Cady R, Farmer K, Dexter J, Schreiber C. Cosensitization of pain and psychiatric comorbidity in chronic daily headache. *Curr Pain Headache Rep.* 2005;9:47-52.
54. Rome H, Rome J. Limbically augmented pain syndrome (LAPS): Kindling, corticolimbic sensitization, and the convergence of affective and sensory symptoms in chronic pain disorders. *Pain Med.* 2000;1:7-23.
55. Ajzen I. Perceived behavioral control, self-efficacy, locus of control, and the theory of planned behavior. *J Appl Soc Psychol.* 2002;32:665-683.
56. Overmier J, Seligman M. Effects of inescapable shock upon subsequent escape and avoidance responding. *J Comparat Physiol Psychol.* 1967;63:28-33.
57. Overmier J. On learned helplessness. *Integrat Physiol Behav Sci.* 2002;37:4-8.
58. Watkins L, Maier S. Immune regulation of central nervous system functions: From sickness responses to pathological pain. *J Inter Med.* 2005;257:139-155.
59. Weiss J, Goodman P, Losito B, Corrigan S, Charry J, Bailery W. Behavioral depression produced by an uncontrollable stressor: Relationship to norepinephrine, dopamine, and serotonin levels in various regions of the rat brain. *Brain Res Rev.* 1981;3:167-205.
60. French DJ, Holroyd KA, Pinell C, Malinoski PM, O'Donnell F, Hill KR. Perceived self-efficacy and headache-related disability. *Headache.* 2000;40:647-656.
61. Hudzinski L, Levenson H. Biofeedback behavioral treatment of headache with locus of control pain analysis: A 20-month retrospective study. *Headache.* 1985;25:380-386.
62. Scharff L, Turk DC, Marcus DA. The relationship of locus of control and psychosocial-behavioral response in chronic headache. *Headache.* 1995;35:527-533.
63. Martin NJ, Holroyd KA, Penzien DB. The headache-specific locus of control scale: Adaptation to recurrent headaches. *Headache.* 1990;30:729-734.
64. Bandura A, O'Leary A, Taylor C, Gauthier J, Gosard D. Perceived self-efficacy and pain control: Opioid and nonopioid mechanisms. *J Personal Social Psychol.* 1987;53:563-571.
65. Bandura A. *Self-efficacy: The Exercise of Control.* New York: W.H. Freeman and Company; 1997.

66. Marlowe N. Self-efficacy moderates the impact of stressful events on headache. *Headache*. 1998;38:662-667.
67. Maizels M. Why should physicians care about behavioral research? *Headache*. 2005;45:411-413.
68. Andrasik F. Behavioral treatment approaches to chronic headache. *Neurol Sci*. 2003;24(suppl 2):S80-S85.
69. Lake AI. Behavioral and nonpharmacologic treatments of headache. *Med Clin North Am*. 2001;85:1055-1075.
70. Nicholson RA, Hursey KG, Nash J. Moderators and mediators of behavioral treatment for headache. *Headache*. 2005;45:513-519.
71. Penzien D, Rains J, Lipchik G, Nicholson R, Lake A, Hursey K. Future directions in behavioral headache research: Applications for an evolving health care environment. *Headache*. 2005;45:526-534.
72. Holroyd K, Penzien D, Hursey K, et al. Change mechanisms in EMG biofeedback training: Cognitive changes underlying improvements in tension headache. *J Consult Clin Psychol*. 1984;52:1039-1053.
73. Gauthier JG, Lacroix R, Cote A, Doyon J, Drolet M. Biofeedback control of migraine headaches: A comparison of two approaches. *Biofeedback Self Regul*. 1985;10:139-159.
74. Blanchard EB, Kim M, CU H, Steffek BD. Preliminary results of the effects on headache relief of perception of success among tension headache patients receiving relaxation. *Headache Quarterly*. 1993;4:249-253.
75. Rokicki LA, KA H, France CR, GL L, France JL, Kvaal SA. Change mechanisms associated with combined relaxation/EMG biofeedback training for chronic tension headache. *Appl Psychophysiol Biofeedback*. 1997;22:21-41.
76. Smith T, Nicholson R. Are changes in cognitive and emotional factors important in improving in headache impact and quality of life? *Headache*. 2006;46:878.
77. Nicholson RA, Nash J, Andrasik F. A self-administered behavioral intervention using tailored messages for migraine. *Headache*. 2005;45:1124-1139.
78. Bond D, Dirge K, Rubingh C, Durrant L, Baggailey S. Impact of a self-help intervention on performance of headache management behaviors: A self-efficacy approach. *Internet J Allied Health Sci Practice*. 2004;2.
79. Anderson K, Dowds B, Pelletz R, Edwards W, Peeters-Asdourian C. Development and initial validation of a scale to measure self-efficacy beliefs in patients with chronic pain. *Pain*. 1995;63:77-84.
80. Martin NJ, Holroyd KA, Rokicki LA. Headache self-efficacy scale: Adaptation to recurrent headaches. *Headache*. 1993;33:244-248.
81. Marlowe N. Stressful events, appraisal, coping, and recurrent headache. *J Clin Psychol*. 1998;54:247-256.
82. Bandura A, Cioffi D, Taylor CB, Brouillard ME. Perceived self-efficacy in coping with cognitive stressors and opioid activation. *J Personal Soc Psychol*. 1988;55:479-488.
83. Breslau N, Rasmussen BK. The impact of migraine: Epidemiology, risk factors, and co-morbidities. *Neurology*. 2001;56:S4-S12.
84. Ferrari MD, Haan J. Genetics of headache. In: Silberstien SD, Lipton RB, Dalessio DJ, eds. *Wolff's Headache and Other Head Pain*. 7th ed. New York: Oxford; 2001:73-84.
85. Martin VT. Toward a rational understanding of migraine trigger factors. *Med Clin North Am*. 2001;85:911-941.
86. Nicholson R, Smith T. Predicting self-efficacy, satisfaction with care, and headache impact among migraine sufferers in a primary care setting. *Headache*. 2006;46:874.
87. Penzien D, Rains J, Lipchik G, Creer T. Behavioral interventions for tension-type headache: Overview of current therapies and recommendation for a self-management model for chronic headache. *Curr Pain Headache Rep*. 2004;8:489-499.
88. Watson D, Clark LA. Negative affectivity: The disposition to experience aversive emotional states. *Psychol Bull*. 1984;96:465-490.
89. Watson D, Pennebaker JW. Health complaints, stress, and distress: Exploring the central role of negative affectivity. *Psychol Rev*. 1989;96:234-254.
90. Zwart J, Dyb G, Hagen K, et al. Depression and anxiety disorders associated with headache frequency. The Nord-Trøndelag Health Study. *Eur J Neurol*. 2003;10:147-152.
91. White K, Farrell A. Anxiety and psychosocial stress as predictors of headache and abdominal pain in urban early adolescents. *J Pediatric Psychol*. 2006;31:582-596.

92. Boardman H, Thomas E, Millson D, Croft P. Psychological, sleep, lifestyle, and comorbid associations with headache. *Headache*. 2005;45:657-669.
93. Holroyd KA, Stensland M, Lipchik GL, Hill KR, O'Donnell F, Cordingly G. Psychosocial correlates and impact of chronic tension-type headaches. *Headache*. 2000;40:3-16.
94. Janke E, KA H, Romanek K. Depression increases onset of tension-type headache following laboratory stress. *Pain*. 2004;111:230-238.
95. Perozzo P, Savi L, Castelli L, et al. Anger and emotional distress in patients with migraine and tension-type headache. *J Headache Pain*. 2005;6:392-399.
96. Fernandez E, Milburn TW. Sensory and affective predictors of overall pain and emotions associated with affective pain. *Clin J Pain*. 1994;10:3-9.
97. Keefe F, Lumley M, Anderson T, Lynch T, Carson K. Pain and emotion: New research directions. *J Clin Psychol*. 2001;57:587-607.
98. Wade JB, Price DD, Hamer RM, Schwartz SM, Hart RP. An emotional component analysis of chronic pain. *Pain*. 1990;40:303-310.
99. Cottrell CK, Drew JB, Waller SE, Holroyd KA, Brose JA, O'Donnell FJ. Perceptions and needs of patients with migraine: A focus group study. *J Family Practice*. 2002;51:142-147.
100. Materazzo F, Cathcart S, Pritchard D. Anger, depression, and coping interactions in headache activity and adjustment: A controlled study. *J Psychosomatic Res*. 2000;49:69-75.
101. Duckro PN, Chibnall JT, Tomazic TJ. Anger, depression, and disability: A path analysis of relationships in a sample of chronic posttraumatic headache patients. *Headache*. 1995;35:7-9.
102. Holroyd KA, Malinoski P, Davis MK, Lipchik GL. The three dimensions of headache impact: Pain, disability and affective distress. *Pain*. 1999/12/1 1999;83:571-578.
103. Nicholson R, Gramling S. The role of anger-in and depression in predicting headache-related disability. Paper presented at: Association for the Advancement of Behavior Therapy 2003; Boston, MA.
104. Hatch JP, Schoenfeld LS, Boutros NN, Seleshi E, Moore PJ, Cyr-Provost M. Anger and hostility in tension-type headache. *Headache*. 1991;31:302-304.
105. Lang P, Bradley M, Cuthbert B. Motivated attention: Affect, activation, and action. In: Lang P, Simons R, Balaban M, eds. *Attention and Orienting: Sensory and Motivational Processes*. Hillsdale, NJ: Lawrence Erlbaum; 1997:97-135.
106. Burstein R. Unitary hypothesis for multiple triggers of the pain and strain of migraine. *J Comparat Neurol*. 2005;493:9-14.
107. Asmundson GJ, Norton PJ, Vlaeyen J. Fear-avoidance models of chronic pain: An overview. In: Asmundson GJ, Vlaeyen JWS, Crombez G, eds. *Understanding and Treating Fear of Pain*. Oxford, UK: Oxford University Press; 2004:3-24.
108. Lydiard R. The role of GABA in anxiety disorders. *J Clin Psychol*. 2003;64:21-27.
109. Crestani F, Lorez M, Baer K, et al. Decreased GABAA-receptor clustering results in enhanced anxiety and a bias for threat cues. *Nature Neurosci*. 1999;2:833-839.
110. Low K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. *Science*. 2000;290:131-134.
111. Storer R, Akerman S, Shields K, Goadsby PJ. GABAA receptor modulation of trigeminovascular nociceptive neurotransmission by midazolam is antagonized by flumazenil. *Brain Res*. 2004;1013:188-193.
112. Mulleners W, Chronicle E, Vredevelde J, Koehler P. Visual cortex excitability in migraine before and after valproate prophylaxis: A pilot study using TMS. *Eur J Neurol*. 2002;9:35-40.
113. Breslau N. Migraine, suicidal ideation, and suicide attempts. *Neurology*. 1992;392-395.
114. Silberstein SD. Serotonin (5-HT) and migraine. *Headache*. 1994;34:498-517.
115. Dougherty DD, Shin LM, Alpert NM, et al. Anger in healthy men: A PET study using script-driven imagery. *Soci Biol Psychiatry*. 1999;46:466-472.
116. Hariri A, Bookheimer S, Mazziotta J. Modulating emotional responses: Effects of a neocortical network on the limbic system. *Neuroreport*. 2000;11:43-48.
117. Rainville P. Brain mechanisms of pain affect and pain modulation. *Curr Opin Neurobiol*. 2002;12:195-204.
118. Barlow D. Unraveling the mysteries of anxiety and its disorders from the perspective of emotion theory. *Am Psychol*. 2000;55:1247-1263.
119. Barlow D. *Anxiety and its Disorders: The Nature and Treatment of Anxiety and Panic*, 2nd ed. New York: Guilford; 2000.

120. Nash J, Theborge R. Understanding psychological stress, its biological processes, and impact on primary headache. *Headache*. 2006;46.
121. Rasmussen B. Migraine and tension-type headache in a general population: Precipitating factors, female hormones, sleep pattern and relation to lifestyle. *Pain*. 1993;53:65-72.
122. Lanteri-Minet M, Radat F, Chautard M, Lucas C. Anxiety and depression associated with migraine: Influence on migraine subjects' disability and quality of life, and acute migraine management. *Pain*. 2005;118:319-326.
123. Nicholson R, Rooney M, Vo K, O'Laughlin E, Gordon M. Headache care among different ethnicities: Do disparities exist? *Headache*. 2006;46:754-765.
124. Scharff L, Turk DC, Marcus DA. Triggers of headache episodes and coping responses of headache diagnostic groups. *Headache*. 1995;35:397-403.
125. Holm JE, Lokken C, Myers TC. Migraine and stress: A daily examination of temporal relationships in women migraineurs. *Headache*. 1997;37:553-558.
126. Fichtel A, Larsson B. Psychosocial impact of headache and comorbidity with other pains among Swedish school adolescents. *Headache*. 2002;42:766-775.
127. Harpole L, Samsa G, Matchar DB, Silberstein SD, Blumenfeld A, Jurgelski A. Burden of illness and satisfaction with care among patients with headache seen in a primary care setting. *Headache*. 2005;45:1048-1055.
128. Marcus D. Headache and other types of chronic pain. *Headache*. 2003;43:49-53.
129. Bishop KL, Holm JA, Borowiak DM, Wilson BA. Perceptions of pain in women with headache: A laboratory investigation of the influence of pain-related anxiety and fear. *Headache*. 2001;41:494-499.
130. McCracken LM, Turk DC. behavioral and cognitive-behavioral treatment for chronic pain: Outcome, predictors of outcome, and treatment process. *Spine*. 2002;27:2564-2573.
131. Breuner C. Factors related to school absenteeism in adolescents with recurrent headache. *Headache*. 2004;44:217-222.
132. Wu L, Parkerson G, Doraiswamy PM. Health perception, pain, and disability as correlates of anxiety and depression symptoms in primary care patients. *J Am Board Family Practice*. 2002;15:183-190.
133. Lafata J, Moon C, Leotta C, Kolodner K, Poisson L, RB L. The medical care utilization and costs associated with migraine headache. *J Gen Inter Med*. 2004;19:1005-1012.
134. Nash J, Williams D, Nicholson R, Trask P. The contribution of pain-related anxiety to disability from headache. *J Behav Med*. 2006;29.
135. Norton PJ, Asmundson GJ. Amending the fear-avoidance model of chronic pain: What is the role of physiological arousal? *Behav Ther*. 2003;34:17-30.
136. Norton PJ, Asmundson GJ. Anxiety sensitivity, fear, and avoidance behavior in headache pain. *Pain*. 2004;111:218-223.
137. Vlaeyen J, Linton SJ. Fear-avoidance and its consequences in chronic musculoskeletal pain: A state of the art. *Pain*. 2000;85:317-332.
138. Reiss S, Peterson R, Gursky D, McNally R. Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. *Behav Res Ther*. 1986;24:1-8.
139. Salkovskis P, Clark D. Panic disorder and hypochondriasis. *Adv Behav Res Ther*. 1993;15:23-48.
140. Asmundson GJ, Taylor S. Role of anxiety sensitivity in pain-related fear and avoidance. *J Behav Med*. 1996;19:577-586.
141. Asmundson GJ, Wright KD, Norton PJ, Veloso F. Anxiety sensitivity and other emotionality traits in predicting headache medication use in patients with recurring headaches: Implications for abuse and dependency. *Add Behav*. 2001;26:827-840.
142. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. 4th ed. Washington, DC: American Psychiatric Association; 1994.
143. Tschannen TA, Duckro PN, Margolis RB, Tomazic TJ. The relationship of anger, depression, and perceived disability among headache patients. *Headache*. 1992;32:501-503.
144. Nicholson RA, Gramling SE, Ong JC, Buenevar L. Differences in anger expression between individuals with and without headache after controlling for depression and anxiety. *Headache*. 2003;43:651-663.
145. Venable VL, Carlson CR, Wilson J. The role of anger and depression in recurrent headache. *Headache*. 2001;41:21-30.
146. Breslau N, Davis GC, Schultz LR, Peterson EL. 1994 Wolff Award Presentation. Migraine and major depression: A longitudinal study. *Headache*. 1994;34:387-393.
147. Blanchard EB, Andrasik F, Applebaum KA, et al. The efficacy and cost-effectiveness of

- minimal-therapist contact, non-drug treatments of chronic migraine and tension headache. *Headache*. 1985;25:214-220.
148. Everson S, Goldberg D, Kaplan G, et al. Hopelessness and risk of mortality and incidence of myocardial infarction and cancer. *Psychosomatic Med*. 1996;58:113-121.
 149. Gesztelyi G, Bereczki D. Determinants of disability in everyday activities differ in primary and cervicogenic headaches and in low back pain. *Psychiatr Clin Neurosci*. 2006;60:271-276.
 150. Stewart W, F, RB L. Need for care and perceptions of MIDAS among headache sufferers study. *CNS Drugs*. 2002;16(suppl 1):5-11.
 151. Marcus DA. Identification of patients with headache at risk of psychological distress. *Headache*. 2000;40:373-376.
 152. Averill J. *Anger and Aggression: An Essay on Emotion*. New York: Springer-Verlag; 1982.
 153. Lazarus R. *Fifty Years of the Research and Theory of R.S. Lazarus: An Analysis of Historical and Perennial Issues*. Mahwah, NJ: Lawrence Erlbaum; 1998.
 154. Smedslund J. How shall the concept of anger be defined? *Theory Psychol*. 1993;3:5-33.
 155. Fernandez E, Turk DC. The scope and significance of anger in the experience of chronic pain. *Pain*. 1995;165-175.
 156. Izard C. Four systems for emotion activation: Cognitive and noncognitive processes. *Psychol Rev*. 1993;100:68-90.
 157. Miller T, Smith T, Turner C, Guijarro M, Hallet A. A meta-analytic review of research on hostility and physical health. *Psychol Bull*. 1996;119:322-348.
 158. Suinn RM. The terrible twos-anger and anxiety. Hazardous to your health. *Am Psychol*. 2001;56:27-36.
 159. Kerns R, Rosenberg R, Jacob M. Anger expression and chronic pain. *J Behav Med*. 1994;17:57-67.
 160. Burns JW, Johnson B, Devine J, Mahoney N, Pawl R. Anger management style and the prediction of treatment outcome among male and female chronic pain patients. *Behav Res Ther*. 1998;36:1051-1062.
 161. Eckhardt C, Deffenbacher J. Diagnosis of anger disorders. In: Kassinove H, ed. *Anger Disorders: Definition, Diagnosis, and Treatment*. Washington, DC: Taylor & Francis; 1995:27-48.
 162. Spielberger C, Reheiser E, Sydeman S. Measuring the experience, expression, and control of anger. In: Kassinove H, ed. *Anger Disorders: Definition, Diagnosis, and Treatment*. Washington, DC: Taylor & Francis; 1995:49-68.
 163. Spielberger CD, Johnson EH, Russell SF, Crane RJ, Jacobs GA, Worden TJ. The experience and expression of anger: Construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, eds. *Anger and Hostility in Cardiovascular and Behavioral Disorders*. New York: Hemisphere; 1985:5-30.
 164. Burns JW. Anger management style and hostility: Predicting symptom-specific physiological reactivity among chronic low back pain patients. *J Behav Med*. 1997;20:505-522.
 165. Kearns RD, Rosenberg R, Jacob MC. Anger expression and chronic pain. *J Behav Med*. 1994;17:57-67.
 166. Deffenbacher JL, Oetting ER, Lynch RS, Morris CD. The expression of anger and its consequences. *Behav Res Ther*. 1996;34:575-590.
 167. Pilowski I, Spence ND. Pain, anger, and illness behavior. *J Psychosomatic Res*. 1976;20:411-416.
 168. Nicholson RA, Gramling SE, Ong JC. *The Role of Anger in Predicting Headache-Related Disability*. Paper presented at: American Headache Society, 2003; Chicago, IL.
 169. Fernandez E, Turk DC. Sensory and affective components of pain: Separation and synthesis. *Psychol Bull*. 1992;112:205-217.
 170. Bruehl S, Burns JW, Chung OY, Ward P, Johnson B. Anger and pain sensitivity in chronic low back pain patients and pain-free controls: The role of endogenous opioids. *Pain*. 2002;99:223-233.
 171. Burns JW, Bruehl S, Caceres C. Anger management style, blood pressure reactivity, and acute pain sensitivity: Evidence for "trait x situations" models. *Ann Behav Med*. 2004;27:195-204.
 172. Bigal ME, Lipton R. Modifiable risk factors for migraine—Clinical lessons. *Headache*. 2006;46.
 173. Scher AI, Lipton R, Stewart W. Risk factors for chronic daily headache. *Curr Pain Headache Rep*. 2002;6:486-491.
 174. Houle T, Remble T, Houle T. The examination of headache activity using time-series research designs. *Headache*. 2005;45:438-444.
 175. Goadsby PJ, Lipton RB, Ferrari MD. Migraine—current understanding and treatment. *N Engl J Med*. 2002;346:257-270.
 176. Bain P. The migraine threshold. *ACHE Newslett*. 2002;13:2.

177. McCrory DC, Penzien DB, Rains JC, Hasselblad V. Efficacy of behavioral treatments for migraine and tension-type headache: Meta-analysis of controlled trials. *Headache*. 1996;36:272.
178. McCrory DC, Penzien DB, Hasselblad V, Gray RN. *Evidence Report: Behavioral and Physical Treatments for Tension-type and Cervicogenic Headache*. Des Moines, IA: Foundation for Chiropractic Education and Research (Product No. 2085); 2001.
179. Campbell K, Penzien D, Wall J. Evidence-based guidelines for migraine headache in the primary care setting: Behavioral and physical intervention for prevention of migraine. *Am Acad Neurol. (online)* April 2000, Retrieved October 15, 2002 2000.
180. Strom L, Pettersson R, Andersson G. A controlled trial of self-help treatment of recurrent headache conducted via the internet. *J Consulting Clin Psychol*. 2000;68:722-727.
181. Holroyd KA, Penzien DB, Lipchik GL. Behavioral management of headache. In: Silberstien SD, Lipton RB, Dalessio DJ, eds. *Wolff's Headache and Other Head Pain*. 7th ed. New York: Oxford; 2001:562-598.

Copyright of Headache: The Journal of Head & Face Pain is the property of Blackwell Publishing Limited and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.